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ABSTrACT
Background: Based on the hypothesis that the neointima found 
in drug-eluting stents (DES) with biodegradable polymers at 
28 days is not a definitive neointima and that optical coher-
ence tomography (OCT) is an effective method for sequential 
neointimal evaluation, we aim, in this experimental study, to 
compare OCT findings at 28 and 90 days, in two different 
DES with biodegradable polymers: the sirolimus-eluting stent 
(Inspiron®, Scitech) and the biolimus A9-eluting stent (Biomatrix®, 
Biosensors International). Methods: Overall, 6 non-atherosclerotic 
pigs were submitted to the implantation of 6 Inspiron® stents 
and 6 Biomatrix® stents. Each pig received both stent types, 
one in each coronary artery (left anterior descending artery 
and circumflex artery) and after 28 and 90 days qualitative 
in-stent OCT analyses were performed at 1-millimeter inter-
vals. results: Qualitative assessment was performed in-stent 
pairing millimeter by millimeter. Heterogeneous neointimal 
tissue was evidenced in 39% at 28 days and in 0% at 90 
days, the presence of intraluminal tissue in 18% at 28 days 
and in 0% at 90 days, luminal irregularity in 62% at 28 days 
and in 2% at 90 days (P < 0.005). There was no difference 
between groups regarding the quality of the neointima over 
time (P > 0.05). Conclusions: The OCT findings corroborate 
the hypothesis that the neointima found in DES with biode-
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rESUMO
Evolução Temporal da Proliferação Neointimal após 
Implante de Dois Tipos de Stent Farmacológico 
com Polímeros Biodegradáveis em Modelo Porcino: 
Avaliação Qualitativa por Tomografia de  
Coerência Óptica Sequencial
Introdução: Baseados na hipótese de que a neoíntima encontrada 
em stents farmacológicos (SFs) com polímeros biodegradáveis 
aos 28 dias não é a neoíntima definitiva e de que a tomogra 
fia de coerência óptica (TCO) é um método eficaz para a 
avaliação sequencial da neoíntima, objetivamos, neste estudo 
experimental, comparar os achados da TCO aos 28 dias e aos 
90 dias em dois tipos de SF com polímeros biodegradáveis: o 
stent liberador de sirolimus (Inspiron®, Scitech) e o stent liberador 
de biolimus A9 (Biomatrix®, Biosensors International). Métodos: 
No total, 6 porcos não-ateroscleróticos foram submetidos a 
implante de 6 stents Inspiron® e de 6 stents Biomatrix®. Cada 
porco recebeu os dois tipos de stent, um em cada artéria 
coronária (descendente anterior e circunflexa) e após 28 dias 
e 90 dias foram rea lizadas avaliações qualitativas intrastent 
a cada milímetro com TCO. resultados: A avaliação quali-
tativa, feita por pareamento milímetro a milímetro intrastent, 
evidenciou neoíntima heterogênea em 39% aos 28 dias e em 
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gradable polymers at 28 days is not a definitive neointima. 
The most significant experimental evidence is the change in 
the neointimal characteristics observed at sequential OCT.
 
 
 
 
 
 
 
DESCrIPTOrS: Tomography, optical coherence. Drug-eluting 
stents. Angioplasty. Polymers. Neointima.
Methods
All procedures followed the standards for labora-
tory animal protection and care established by the 
Ethical Principles in Animal Experimentation of the 
Research Support and Animal Experimentation Service 
of the Instituto do Coração da Faculdade de Medicina 
da Universidade de São Paulo, as well as the Guide 
for the Care and Use of Laboratory Animals (Institute 
of Laboratory Animal Resources, Commission on Life 
Sciences and National Research Council, National 
Academy Press, Washington, DC, 1996) and the Ethical 
Principles in Animal Experimentation of the Brazilian 
College of Animal Experimentation (COBEA).
subjects and stent implantation
Six domestic juvenile, non-atherosclerotic pigs, 
weighing between 18 kg and 23 kg, were obtained 
from a commercial breeding farm.
One day before the procedure, the pigs received 
600 mg of acetylsalicylic acid and 150  mg of clopi-
dogrel orally. The anaesthesia protocol consisted of 
premedication (ketamine 3  mg/kg and midazolam 0.5 
mg/kg, intramuscular) followed by intravenous infusion 
of thiopental, endotracheal intubation, and the start of 
mechanical ventilation; the level of anaesthesia was 
maintained with isoflurane.
A 6F vascular sheath was introduced under direct 
vision after dissection of the common femoral artery. 
A dose of 10,000 IU unfractionated heparin was ad-
ministered and the left coronary artery was selectively 
catheterised under fluoroscopy using a Judkins right 
(JR)4 6F guide catheter. Then, nitroglycerin was injected 
through the catheter at a dose of 200 µg, and an Ins-
piron® or Biomatrix® stent was randomly implanted in 
each anterior descending or circumflex artery of each 
pig, trying to maintain a stent-releasing balloon/artery 
ratio of 1.1/1. The Inspiron® stents were 2.5 mm or 3 
mm in diameter and 16 mm in length. All implanted 
Biomatrix® stents were 3 mm in diameter and 14 mm 
in length.
C urrent knowledge of the vascular response and the resulting neointimal hyperplasia related to the implantation of drug-eluting stents (DES) is 
largely based on preclinical studies in porcine coro-
nary arteries.1-4 In animals, peak neointimal growth 
with bare-metal stents (BMS) occurs at 28 days; 
with DES, studies in animals have shown favourable 
results for re-endothelialization at 28 days, albeit 
incomplete.5-8 
Vascular healing in response to DES implantation is 
dynamic and depends on the type of drug used, which 
in turn depends on its release kinetics from durable or 
biodegradable polymers.9-16 Evaluation through histology 
does not allow for time-dependent analyses, and there 
are additional limitations, such as tissue loss related 
to the technique employed for material preparation 
(non-satisfactory cutting or colouring, thickness, and 
angle of the cut).
Due to its high resolution, optical coherence 
tomography (OCT) may be a promising intravascular 
imaging tool in the sequential evaluation of neointimal 
formation. Compared to histology, OCT allows for the 
evaluation of the vascular healing process in vivo at 
different stages, providing qualitative and quantitative 
information along the full length of the stent.17-20 By 
enabling analysis at multiple time points, it is possible 
to compare the same intrastent region at different 
times and thereby assess temporal neointima matura-
tion, as well as to evaluate each intrastent millimetre 
strut by strut.
Based on the hypothesis that the neointima found 
in DES with biodegradable polymers at 28 days are not 
definitive, and that OCT is an effective method for the 
sequential evaluation of neointima, this experimental 
study aimed to compare the qualitative findings of 
OCT at 28 days and 90 days in two types of DES with 
biodegradable polymers: the sirolimus-eluting stent 
(Inspiron®, Scitech Medical Products Ltda. – Goiânia, 
Brazil) and the biolimus-A9 eluting stent (Biomatrix®, 
Biosensors International – Singapore).
0% aos 90 dias, presença de tecido intraluminal em 18% aos 
28 dias e em 0% aos 90 dias, irregularidade luminal em 62% 
aos 28 dias e em 2% aos 90 dias (P < 0,005). Não houve 
diferença entre os grupos quanto à qualidade da neoíntima 
ao longo do tempo (P > 0,05). Conclusões: Os achados à 
TCO corroboram a hipótese de que a neoíntima encontrada 
em SFs com polímeros biodegradáveis aos 28 dias não é a 
neoíntima definitiva. A evidência experimental mais significa-
tiva é a mudança das características da neoíntima observada 
à TCO sequencial.
DESCrITOrES: Tomografia de coerência óptica. Stents farma-
cológicos. Angioplastia. Polímeros. Neoíntima.
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optical coherence tomography
An M2 OCT Imaging System (Imaging LightLab, Inc., 
Westford, USA) was used with ImageWire® automated 
catheter pullback (LightLab Imaging, Inc.) at a speed 
of 1 mm/s and 2 mm/s after proximal occlusion of the 
arterial segment under study with a Helios® balloon 
(LightLab Imaging, Inc.). Specific software from the 
OCT equipment was used to make measurements at 1 
mm intervals starting from the most distal part of the 
stent and moving towards the proximal end.
Morphometric Analysis
The first stent image analysed was the one that 
allowed for the drawing of a complete circle using 
struts in the distal border. The stent and luminal areas 
were measured by manual tracing (mm2). The neointimal 
area (mm2) was calculated as the lumen area minus 
the stent area. The neointimal area percentage (%) 
was calculated as the ratio between the neointimal 
area and the stent area (neointimal area percentage 
= area of the stent – lumen area/stent area). For the 
analysis of neointimal thickness (mm), the distance 
from the luminal surface of the stent strut reflec-
tion (called the “blooming artifact”) to the luminal 
contour was measured. Since the blooming artefact 
was systematically included in the measurements, to 
determine strut apposition it was necessary to take 
into account its total thickness (thickness of the metal 
strut + thickness of the polymer + drug) plus a cor-
rection factor of 20 µm, which corrects for the actual 
location of the strut surface by discounting half of the 
blooming.18,19 The distance between the luminal surface 
of blooming produced by the struts and the contour 
of the vascular lumen was analysed indivi dually for 
each strut. For the stents in this study, if the distance 
was greater than the sum of the thicknesses of the 
struts (Biomatrix®, 112  µm; Inspiron®, 75 µm) plus 
the thicknesses of the polymers (Biomatrix®, 10 µm; 
Inspiron®, 5 µm) plus 20 µm (correction factor), the 
strut would be considered malpositioned.
Characterisation of neointimal tissue
The qualitative analysis evaluated transverse sec-
tions at each millimetre along the stent at 28 and 90 
days. Features such as the presence of neointima with 
luminal irregularities, the presence of intraluminal tis-
sue, and the heterogeneous aspects of neointima were 
detected and described.
Neointimal tissue with irregularities was defined 
by the presence of indistinct and irregular contours on 
the luminal surface of the vessel and by the presence 
or absence of discontinuous neointima. Intraluminal 
tissue was identified as material protruding into the 
vessel lumen, which may or may not adhere to the 
neointima. Heterogeneous aspects of neointimal tissue 
were identified when an image with low light intensity 
was observed in the OCT of neointimal tissue without 
signal attenuation behind the area (Figure 1).
These events were compared in cross-sectional 
OCT images taken after 28 and 90 days and evaluated 
regarding their progression or resolution.
statistical Analysis
Data are shown as the mean ± SD or as numbers 
and percentages. The comparison between days 28 and 
90, as well as the interaction of the effects of the type 
of stent and the progression/regression of the temporal 
neointima over time were analysed with a general linear 
model with repeated measures. The significance level 
was set at 5%. Analyses were performed using SPSS 
20.0 (IBM SPSS – Chicago, USA).
Results
All six pigs survived the index procedure and 
underwent angiographic analysis and OCT at 28 days 
and at 90 days after implantation.
In total, 2,685 stent struts along 350 mm of total 
stent length were analysed (1,366 struts at 28 days and 
1,319 struts at 90 days); 338 paired transverse sections 
were analysed at 28 days and at 90 days (Inspiron® = 
90 and Biomatrix® = 79 transverse sections analysed 
at each time point) (Figure 2). Twelve transverse sec-
tions were excluded from the analysis due to image 
artifacts. No malpositioned struts were observed, as 
all struts analysed were covered by neointimal tissue.
Events such as the presence of luminal irregulari-
ties, heterogeneous aspects of neointimal tissue, and the 
presence of intraluminal tissue were evaluated in the 
12 stents at 28 days. The presence of heterogeneous 
neointimal tissue, irregular lumen, and luminal tissue 
in the transverse sections was higher at 28 days than 
at 90 days (38.8 ± 28.2% vs. 0%; P = 0.001; 62.4 ± 
23.1% vs. 2.2 ± 5.1%; P < 0.001; 17.9 ± 16.3% vs. 0%; 
P = 0.005, respectively). This behaviour was observed 
for both stents analysed (Table 1).
The incidence of qualitative events in the trans-
verse sections analysed was similar at 28 days for 
both stents, and each showed heterogeneous neointi-
mal tissue (44.4% ± 31.1 and 33.2  ±  26.6% for the 
Inspiron® and Biomatrix® stents, respectively; P = 0.5), 
intraluminal tissue (18.1 ± 20.7% and 17.7 ± 12.5% for 
Inspiron® and Biomatrix® stents, respectively; P > 0.9) 
and luminal irregularities (67.9 ± 20% and 56.9 ± 
26.4% for Biomatrix® and Inspiron® stents, respectively; 
P = 0.5) (Table 1).
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endothelialisation may play an important role in the 
pathogenesis of DES thrombosis.23,24 Additionally, autopsy 
studies have identified the presence of bare struts as a 
more robust morphological predictor for the occurrence 
of thrombosis in first-generation DES.25 
The present study with sequential OCT, despite not 
showing bare struts, did provide images that indicate 
disCussion
Several studies in animal models and previous 
clinical trials showed delayed endothelialisation of 
DES when compared to BMS,21-23 and observed the 
frequent presence of struts covered by thin layers of 
neointimal tissue, with a thickness well below the limits 
of detection by intracoronary ultrasound. This delayed 
Figure 1 – Optical coherence tomography images of a cross-section of porcine coronaries with DES. In A, intraluminal tissue, which is material that 
is located in the vessel lumen and may or may not adhere to the neointimal tissue. In B, neointimal tissue with irregularities, showing the presence 
of irregular and indistinct borders of the luminal surface of the vessel with the presence or absence of discontinuous neointima. In C, heterogeneous 
aspects of neointimal tissue are depicted in the image showing low light intensity of neointimal tissue near the stent struts. In D, homogeneous 
aspects of neointimal tissue with light intensity compatible with normal neointima are shown.
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Table 1 
Quantitative and qualitative findings from sequential optical coherence tomography images taken  
at 28 and 90 days after Inspiron® and Biomatrix® stent implantation in porcine coronary arteries
28 days 90 days
P 
(28 days 
vs. 90  
days
P 
(Interaction 
Inspiron® vs. 
Biomatrix®)
Inspiron® 
(n = 90)
Biomatrix® 
(n = 79)
Global
(n = 169)
Inspiron® 
(n = 90)
Biomatrix® 
(n = 79)
Global 
(n = 169)
Luminal area, mm2 3.29 ± 0.96 3.94 ± 0.46 3.62 ± 0.76 3.24 ± 0.94 3.75 ± 0.99 3.50 ± 0.96 0.6 0.8
Stent area, mm2 5.32 ± 0.78 5.75 ± 0.38 5.53 ± 0.62 5.45 ± 0.94 5.85 ± 0.57 5.65 ± 0.77 0.5 0.9
NIH percentage 
load, %
39.2 ± 11 31.1 ± 10.3 35.2 ± 11 40.9 ± 10 35.3 ± 17.6 38.1 ± 13.9 0.4 0.8
NIH area, mm2 2.08 ± 0.35 1.80 ± 0.71 1.92 ± 0.55 2.21 ± 0.58 2.09 ± 1.09 2.15 ± 0.84 0.3 0.8
NIH thickness, 
mm2
0.27 ± 0.06 0.22 ± 0.10 0.24 ± 0.09 0.30 ± 0.08 0.29 ± 0.15 029 ± 0.12 0.1 0.5
TS with 
heterogeneous 
NIH
44.4 ± 31.1 33.2 ± 26.6 38.8 ± 28.2 0 ± 0 0 ± 0 0 ± 0 0.001 0.5
TS with intimal 
irregularity
67.9 ± 20 56.9 ± 26.4 62.4 ± 23.1 2 ± 4.8 2.4 ± 5.8 2.2 ± 5.1 < 0.001 0.5
TS with 
intraluminal tissue
18.1 ± 20.7 17.7 ± 12.5 17.9 ± 16.3 0 ± 0 0 ± 0 0 ± 0 0.005 > 0.9
NIH, neointima hyperplasia; TS, transverse sections.
Figure 2 – Paired optical coherence tomography images of a cross-section of the Inspiron® stent implanted in the left anterior descending artery at 
28 days (A) and 90 days (B). At 28 days, the heterogeneous aspects of the neointimal tissue can be observed, which are replaced by homogeneous 
aspects at 90 days.
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heterogeneity in the healing process after 28 days. This 
result suggests that this is a step in the neointimal tis-
sue maturation process for both stents studied, since, at 
90 days, no heterogeneous neointimal tissue, luminal 
irregularity, and intraluminal tissue were observed.
It should be noted that at both 28 and 90 days, 
although the process of stent endothelialisation is faster 
in pigs than in humans,7 polymers from both Inspiron® 
and Biomatrix® stents are still present and undergoing 
degradation and their respective antiproliferative drugs 
are still present.12,26 A study with a later evaluation time 
point (> six months) may be needed to analyse DES in 
order to evaluate the inflammatory and chronic biological 
responses after drug elution and polymer degradation. 
It will be important to correlate the OCT findings 
with histological data to identify and understand the 
neointima maturation process. Teramoto et al.27 correlated 
images with low light intensity signal visualised in OCT 
with histological findings, and observed areas of low 
cellularity and the presence of fibrin and proteoglycans.
Second-generation OCT systems, which are already 
available for both pre-clinical and clinical use (Fourier-
domain optical coherence tomography [FDOCT]), are 
capable of acquiring images at higher speeds with fewer 
artefacts and without the need for proximal occlusion 
of the coronary artery. Recent FDOCT studies compared 
the optical density of neointimal tissue longitudinally 
after stent implantation to differentiate fibrin from 
neointimal tissue.28,29
These findings corroborate the results of the pres-
ent study, as they demonstrated neointimal maturation 
over time and showed a progressive reduction in the 
amount of fibrin and its replacement by neointimal 
tissue, which was maintained after 28 days.
Further evaluations are needed to better under-
stand the possible roles of these different regions in 
neointimal tissue in the arterial healing process after 
implantation of DES.
study limitations
Qualitative analyses were performed by a single 
investigator; therefore, the assessment of the qualitative 
characteristics of the neointima could be biased despite 
the best efforts to remain objective.
The DES were implanted in porcine non-atheroscle-
rotic coronary arteries and the vascular response was 
evaluated in the context of normal porcine coronary 
arteries. Preclinical studies with these stents in the 
arteries of animals with experimental atherosclerosis 
(minipigs, rabbits) can mora accurately answer the 
questions regarding the effectiveness of these stents.21 
ConClusions
The OCT results corroborate the hypothesis that the 
neointima found in DES with biodegradable polymers 
at 28 days is not the definitive neointima. The most 
significant experimental evidence is the change in 
characteristics of the neointima observed in OCT images 
taken after 90 days. This fundamental tool is useful in 
the preclinical analysis of stents, allowing the sequential 
assessment of neointimal tissue in vivo.
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